Who are TMC114/rtv's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lopinavir/ritonavir and raltegravir, protease inhibitors, Fosamprenavir/ritonavir, Lopinavir/ritonavir simplification strategy, continue on current dual boosted PI, Atazanavir, ritonavir, lamivudine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tmc114-rtv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TMC114/rtv — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TMC114/rtv (TMC114/rtv) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious disease.

phase 3 protease inhibitor HIV protease Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

TMC114/rtv (TMC114/rtv) — Tibotec Pharmaceuticals, Ireland. TMC114/rtv is a protease inhibitor used to treat HIV infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TMC114/rtv TARGET	TMC114/rtv	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV protease
lopinavir/ritonavir and raltegravir	lopinavir/ritonavir and raltegravir	Saint Michael's Medical Center	marketed	Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir)	HIV protease (lopinavir/ritonavir) and HIV integrase (raltegravir)
protease inhibitors	protease inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Protease inhibitor	HIV protease
Fosamprenavir/ritonavir	Fosamprenavir/ritonavir	ViiV Healthcare	marketed	HIV protease inhibitor	HIV protease
Lopinavir/ritonavir simplification strategy	Lopinavir/ritonavir simplification strategy	Fundación Huésped	marketed	Protease inhibitor combination	HIV protease
continue on current dual boosted PI	continue on current dual boosted PI	Community Research Initiative of New England	marketed	Protease inhibitor (PI) combination with pharmacokinetic booster	HIV protease
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (protease inhibitor class)

Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
AbbVie · 1 drug in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class
R-Pharm · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TMC114/rtv — Competitive Intelligence Brief. https://druglandscape.com/ci/tmc114-rtv. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing